Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px
Document › Details

Agilent Technologies Inc.. (5/31/18). "Press Release: Agilent Technologies Completes Acquisition of Advanced Analytical Technologies, Inc.". Santa Clara, CA.

Organisations Organisation Agilent Technologies, Diagnostics and Genomics Group (DGG)
  Organisation 2 Advanced Analytical Technologies Inc. (AATI)
Products Product capillary electrophoresis (CE)
  Product 2 laboratory equipment and instruments
Index term Index term Advanced Analytical–Agilent: investment, 201803–201805 acquisition $250m in cash of Advanced Analytical Technologies Inc by Agilent
Person Person Wadsworth-Hansen, Victoria (Agilent 201506 Director Global Business Public Relations)
     


Agilent Technologies, Inc. (NYSE: A) today announced that it has completed the acquisition of Advanced Analytical Technologies, Inc. (AATI), a provider of capillary electrophoresis-based (CE) solutions for fully-automated analysis of a range of molecules for $250 million in cash.

This acquisition brings together two innovators in the electrophoresis space. Advances in genomics, metabolomics, and proteomics are driving growth and demand for robust, purpose built solutions to analyze biomolecules such as nucleic acids (RNA and DNA), proteins, carbohydrates and small molecules. AATI has developed compelling products based on CE technologies that provide key advances in sensitivity and resolution to address a wide range of applications across a variety of industry segments.

"We are pleased to announce that the transaction is now complete, and we are looking forward to integrating the teams," said Sam Raha, president of Agilent's Diagnostics and Genomics Group. "This acquisition enhances Agilent's existing expertise and technology base, and will allow us to provide customers with a more comprehensive set of solutions for Next Generation Sequencing (NGS) workflows and also for other applications."

AATI's 109 employees will join Agilent as part of the new Biomolecular Analysis Division within its Diagnostics and Genomics Group. The new Biomolecular Analysis Division will also consist of Agilent's existing microfluidics business, which was previously part of Agilent's Life Sciences and Applied Markets Group.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide. Information about Agilent is available at www.agilent.com.
Forward-Looking Statements


This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent's future revenue, earnings and profitability; planned new products; market trends; the future demand for the company's products and services; customer expectations; and revenue and non-GAAP earnings guidance for the third quarter and full fiscal year 2018. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended April 30, 2018. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.


Editorial Contacts

Victoria Wadsworth-Hansen (Business)
+1 408 553 2005
+ 45 29336980
victoria.wadsworth-hansen@agilent.com

Stefanie Notaney (Enterprise)
+1 408 345 8955
stefanie.notaney@agilent.com

Investor Contact

Alicia Rodriguez
+1 408 345 8948
alicia_rodriguez@agilent.com

   
Record changed: 2018-07-04

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px




» top